Pharmacological inhibition of p70S6K using PF-4708671 can significantly reduce the effect of YANK2 on promoting proliferation and reducing the tumorigenicity of glioma cells, which is a new potential target for the treatment of glioma. Here, STK32B is linked to glioma.